Today: 16 May 2026
Kyndryl stock price rebounds again after SEC-linked review shock; what’s next for KD shares
11 February 2026
2 mins read

Kyndryl stock price rebounds again after SEC-linked review shock; what’s next for KD shares

New York, Feb 11, 2026, 16:58 EST — After-hours

  • Kyndryl bounced back in after-hours trading, shares climbing roughly 9% as the stock recouped ground lost in Monday’s sharp drop.
  • The company has pushed back its quarterly filing as the audit committee investigates internal controls and how cash has been handled.
  • Now, investors are eyeing the overdue Form 10-Q, as well as any repercussions tied to recent shifts in leadership.

Kyndryl Holdings shares jumped roughly 9% to $12.12 late Wednesday, extending a rebound after the IT infrastructure outfit’s stock took a beating earlier this week. The NYSE stock moved between $11.18 and $12.27 on the day.

Investors are now wrestling with a late quarterly report and a high-level probe, as Kyndryl’s internal controls face scrutiny. The company disclosed in a U.S. Securities and Exchange Commission notice that its audit committee is examining cash management and related disclosures. This follows voluntary SEC enforcement requests for documents.

Kyndryl flagged plans to disclose “material weaknesses”—significant holes in its internal controls that could allow for a material misstatement. The company cautioned that both management’s earlier internal control assessment and the auditor’s opinion for the year ended March 31, 2025 “should no longer be relied upon.” For Guggenheim’s Jonathan Lee, the update “draws more questions than answers.” Barron’s

Everything unraveled on Monday: shares plunged nearly 55%—the steepest single-day fall yet—right after Kyndryl announced it was reviewing its books, slashed its guidance, and revealed both CFO David Wyshner and general counsel Edward Sebold were leaving.

Kyndryl’s latest update shows a firm still working to shed its reliance on lower-margin legacy services, aiming instead for expansion in consulting and cloud tie-ups. For the quarter ended Dec. 31, 2025, revenue came in at $3.859 billion, with adjusted earnings at $0.52 a share. Kyndryl Consult’s revenue jumped 24% from a year earlier.

Still, it was the guidance revision that traders zeroed in on. Kyndryl is projecting fiscal 2026 constant-currency revenue to drop by 2% to 3%. Free cash flow? That outlook’s been trimmed, too, now set between $325 million and $375 million.

During the earnings call, CEO Martin Schroeter reiterated the company wasn’t able to discuss the review “until the examination is complete.” He said teams are moving “expeditiously” to deliver a remediation plan. Schroeter flagged longer sales cycles, citing data-sovereignty requirements and rapid shifts in AI that have complicated deals. Investing.com

Analysts wasted no time reworking their forecasts, zeroing in on the consulting business that’s been expanding rapidly. Ian Zaffino at Oppenheimer cut Kyndryl to “Perform” from “Outperform” and scrapped his price target, pointing to drawn-out sales cycles and fresh doubts following the CFO’s exit. TipRanks

Kyndryl pushed ahead with more product updates. The company on Wednesday rolled out a “policy as code” feature for managing agentic AI workflows in regulated environments. Ismail Amla, Kyndryl Consult executive, called it the “structure customers need” as they bring in AI agents. prnewswire.com

The late filing alongside the control warning opens up some clear risks. Should the review drag on, expand, or bring heavier regulatory attention, both customers and investors might hold back, regardless of Kyndryl’s statement that it doesn’t foresee a restatement.

Kyndryl split from IBM back in 2021. It’s in the business of running and updating major IT systems for big companies, up against rivals like DXC Technology and Accenture. The contracts stretch long—so cash flow and how the company reports it are just as important as growth at the top line.

On Thursday, traders are eyeing whether shares can keep their footing after a stretch of sharp moves. The bigger trigger, though, is the overdue Form 10-Q for the Dec. 31 period—details on the cash-management probe, internal controls, and the filing timeline will be in focus.

Stock Market Today

  • DroneShield ASX:DRO Faces Governance Scrutiny Amid ASIC Probe; Valuation Debate Intensifies
    May 15, 2026, 11:08 PM EDT. DroneShield (ASX:DRO) is under an ASIC investigation over executive share trading and announcements from November 2025, raising governance concerns. Despite strong gains over five years with an 18x total shareholder return, recent stock momentum has waned, dropping 12.1% over 30 days to close at A$3.27. Market debate centers on whether this weakness signals a buying opportunity or reflects baked-in growth risks. The leading valuation narrative pegs fair value at A$8.57, implying significant upside based on scalable defence contracts across NATO and US channels. However, the stock's price-to-sales ratio of 13.9x notably exceeds sector averages, indicating elevated valuation risk if growth falters. Investors should weigh potential procurement timing risks and ASIC probe fallout against the company's positioning in the expanding defence technology market.

Latest articles

Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

16 May 2026
U.S. stock ETFs fell in after-hours trading Friday following a more than 1% drop in the S&P 500, Dow, and Nasdaq. Oil surged 4.2% to $105.42 a barrel and the 10-year Treasury yield hit 4.597%, fueling concerns over inflation and Fed rate hikes. Nvidia, AMD, and Intel led chip declines, while Berkshire Hathaway disclosed a $2.65 billion Delta stake and exited Amazon, Visa, and Mastercard.
Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape
Previous Story

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 12.02.2026

Go toTop